Rovin Capital UT ADV Sells 2,770 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Rovin Capital UT ADV cut its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 39.9% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,181 shares of the biopharmaceutical company's stock after selling 2,770 shares during the quarter. Rovin Capital UT ADV's holdings in Gilead Sciences were worth $468,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Norges Bank purchased a new stake in shares of Gilead Sciences during the fourth quarter valued at $1,789,254,000. FMR LLC lifted its stake in Gilead Sciences by 21.6% during the 4th quarter. FMR LLC now owns 40,319,432 shares of the biopharmaceutical company's stock valued at $3,724,306,000 after acquiring an additional 7,157,113 shares during the period. GAMMA Investing LLC boosted its holdings in shares of Gilead Sciences by 13,891.1% during the 1st quarter. GAMMA Investing LLC now owns 2,550,298 shares of the biopharmaceutical company's stock valued at $285,761,000 after acquiring an additional 2,532,070 shares during the last quarter. Northern Trust Corp grew its stake in shares of Gilead Sciences by 19.7% in the fourth quarter. Northern Trust Corp now owns 14,915,095 shares of the biopharmaceutical company's stock worth $1,377,707,000 after acquiring an additional 2,458,954 shares during the period. Finally, Raymond James Financial Inc. purchased a new position in shares of Gilead Sciences during the fourth quarter valued at approximately $207,340,000. Institutional investors own 83.67% of the company's stock.

Gilead Sciences Price Performance

Shares of Gilead Sciences stock traded down $0.24 on Thursday, hitting $111.28. 4,039,652 shares of the company traded hands, compared to its average volume of 7,677,561. The business has a 50-day simple moving average of $106.75 and a 200 day simple moving average of $103.67. Gilead Sciences, Inc. has a 52 week low of $66.01 and a 52 week high of $119.96. The stock has a market capitalization of $138.42 billion, a P/E ratio of 23.43, a price-to-earnings-growth ratio of 0.72 and a beta of 0.29. The company has a debt-to-equity ratio of 1.16, a quick ratio of 1.23 and a current ratio of 1.37.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. The firm had revenue of $6.67 billion during the quarter, compared to analyst estimates of $6.77 billion. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. Gilead Sciences's revenue for the quarter was down .3% compared to the same quarter last year. During the same period last year, the firm posted ($1.32) earnings per share. Research analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, June 27th. Investors of record on Friday, June 13th were issued a dividend of $0.79 per share. The ex-dividend date of this dividend was Friday, June 13th. This represents a $3.16 annualized dividend and a yield of 2.84%. Gilead Sciences's payout ratio is presently 66.53%.

Wall Street Analyst Weigh In

A number of research firms have commented on GILD. JPMorgan Chase & Co. lifted their target price on shares of Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a research report on Thursday, March 27th. Wells Fargo & Company increased their target price on Gilead Sciences from $120.00 to $140.00 and gave the company an "overweight" rating in a report on Wednesday, March 5th. Oppenheimer dropped their target price on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research report on Friday, April 25th. Cantor Fitzgerald started coverage on shares of Gilead Sciences in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 price objective on the stock. Finally, Morgan Stanley boosted their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a research report on Friday, April 25th. Nine investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat, Gilead Sciences has an average rating of "Moderate Buy" and a consensus price target of $110.55.

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the company's stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $110.17, for a total transaction of $275,425.00. Following the transaction, the chief financial officer directly owned 165,110 shares in the company, valued at approximately $18,190,168.70. This represents a 1.49% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Daniel Patrick O'day sold 10,000 shares of the firm's stock in a transaction dated Monday, June 30th. The stock was sold at an average price of $110.45, for a total transaction of $1,104,500.00. Following the completion of the sale, the chief executive officer directly owned 615,725 shares of the company's stock, valued at approximately $68,006,826.25. The trade was a 1.60% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 58,500 shares of company stock worth $6,340,745 over the last three months. 0.27% of the stock is owned by insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.